High through-put screening to repurpose drugs for lupus therapies
Search Results
You searched for: lupus nephritis
Results found: 1152
Belimumab (Benlysta)
In 2011, the FDA approved belimumab (Benlysta®), a B-lymphocyte stimulator (BLyS) protein inhibitor, for adult patients with active, autoantibody-positive, systemic lupus...
Aseptic Meningitis
Aseptic meningitis is a disease caused by the inflammation of the protective membranes covering the brain and spinal cord...
Mechanistic Clinical Awards
The Mechanistic Clinical Award ($750,000 for up to three years) supports pilot studies testing lifestyle interventions in concert with...
Antinuclear Antibodies (ANA)
Any of a group of autoantibodies that react against normal components of the cell nucleus. They are present in...
New targets for treatment of glucocorticoid-resistant lupus
GILZ: glucocorticoid mediator, B cell regulator, and lupus target
Scientific Advisory Board (SAB)
The Scientific Advisory Board is comprised of leading lupus experts. Following the first stage of the peer review process,...
ANA Testing
The antinuclear antibody (ANA) test is commonly used to look for autoantibodies that attack components of your cells’ nucleus,...
Cerebritis
Cerebritis, or inflammation of the brain, can be caused by infection or inflammation from disease.
Lupus Cerebritis is a serious...
Antimalarials
Antimalarials are another type of drug commonly used to treat lupus. These drugs prevent and treat malaria, but doctors...
AMIP – Accelerating Medicines Partnership
The Accelerating Medicines Partnership (AMP) is a bold new venture between the NIH, 10 biopharmaceutical companies and several non-profit...